Engineers Gate Manager’s Tvardi Therapeutics TVRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-854
Closed -$22.8K 2368
2023
Q4
$22.8K Buy
+854
New +$35.4K ﹤0.01% 1899
2023
Q3
Sell
-403
Closed -$41.1K 2133
2023
Q2
$41.1K Buy
+403
New +$55.5K ﹤0.01% 1633
2022
Q3
Sell
-486
Closed -$160K 2152
2022
Q2
$160K Buy
+486
New +$171K 0.01% 1669
2022
Q1
Sell
-588
Closed -$258K 2387
2021
Q4
$258K Sell
588
-450
-43% -$226K 0.01% 1499
2021
Q3
$578K Buy
+1,038
New +$521K 0.03% 786
2021
Q2
Sell
-318
Closed -$249K 2098
2021
Q1
$249K Sell
318
-441
-58% -$302K 0.01% 1447
2020
Q4
$414K Buy
759
+19
+3% +$9.96K 0.02% 1089
2020
Q3
$339K Buy
740
+408
+123% +$237K 0.02% 1183
2020
Q2
$204K Buy
+332
New +$183K 0.01% 1439
2019
Q4
Sell
-284
Closed -$187K 1883
2019
Q3
$187K Buy
+284
New +$236K 0.01% 1221

Other funds holding TVRD

Engineers Gate Manager's TVRD Position: Q1 2024 in Review

Engineers Gate Manager sold out of Tvardi Therapeutics (TVRD) in Q1 2024, closing a stake of 854 shares — an estimated $22.8K sold.

Engineers Gate Manager first reported a position in TVRD in Q3 2019 and held it in 10 quarters. The position peaked at $578K in Q3 2021. 97 funds tracked by Wall St. Rank hold TVRD as of Q1 2024.

  • Engineers Gate Manager reported no remaining Tvardi Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Engineers Gate Manager sold 854 Tvardi Therapeutics shares in Q1 2024, an estimated $22.8K.
  • Engineers Gate Manager first reported a position in Tvardi Therapeutics in Q3 2019 and held it in 10 quarters.
  • Engineers Gate Manager's Tvardi Therapeutics position peaked at $578K in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2024.

Based on Engineers Gate Manager's 13F filing for Q1 2024, filed 15 May 2024.